Facebook
Twitter
Telegram
Report an ErrorGalectin Therapeutics Financial Ratios 2011-2024 | GALT
Annual Financial Ratios Galectin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3.5 | -3.0 | -3.6 | -4.8 | -10.4 | -14.0 | -10.4 | -1.4 | -1.7 | -4.5 | -18.0 | -4.1 | -5.3 |
P/S |
- | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.7 | -0.7 | -0.5 | -0.4 | -0.4 | -0.4 | -0.5 | -0.8 | -0.9 | -0.8 | -1.3 | -0.7 | -1.1 |
EV (Enterprise Value) |
207 M | 151 M | 109 M | 90 M | 93.3 M | 188 M | 169 M | 17.6 M | 9.52 M | 42.9 M | 209 M | 32.4 M | 60.6 M |
EBITDA per Share |
- | - | -0.52 | -0.411 | -0.257 | -0.344 | -0.457 | -0.735 | -0.832 | -0.706 | -0.717 | -0.654 | -0.868 |
EV/EBITDA |
-1.9 | -3.6 | -6.7 | -13.7 | -10.2 | -0.6 | -0.4 | -2.7 | -17.1 | -3.1 | -5.0 | ||
PEG |
0.24 | 13.99 | 0.87 | 3.94 | -0.62 | -0.29 | -0.1 | 0.13 | -0.11 | 0.22 | -0.13 | 0.3 | |
P/B |
-2.4 | -3.6 | 41.8 | 4.6 | 3.0 | 28.1 | 141.4 | 2.4 | 1.4 | 2.5 | 26.4 | 5.1 | -27.4 |
P/CF |
-4.4 | -3.7 | -4.5 | -5.4 | -12.7 | -19.1 | -10.6 | -1.8 | -2.0 | -5.7 | -29.0 | -5.3 | -10.3 |
ROE % |
66.27 | 114.33 | -3418.48 | -96.99 | -29.16 | -201.51 | -1360.85 | -178.41 | -79.95 | -56.44 | -146.93 | -122.21 | 513.65 |
ROA % |
-145.62 | -182.18 | -72.98 | -79.27 | -27.43 | -154.34 | -390.17 | -135.71 | -75.84 | -53.20 | -112.83 | -101.19 | -165.08 |
ROCE % |
61.44 | 113.08 | -3379.51 | -96.96 | -29.44 | -197.19 | -1361.86 | -178.78 | -80.16 | -55.16 | -147.13 | -124.94 | -236.73 |
Current Ratio |
0.3 | 0.4 | 1.1 | 5.5 | 17.1 | 4.2 | 1.3 | 4.2 | 19.4 | 17.4 | 4.3 | 5.8 | 2.9 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Galectin Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.19 | - | -0.24 | -0.15 | -0.19 | - | -0.14 | -0.16 | -0.17 | - | -0.14 | -0.15 | -0.11 | - | -0.1 | -0.11 | -0.06 | - | -0.05 | -0.06 | -0.2 | - | 0.07 | 0.11 | 0.12 | - | -0.13 | -0.14 | -0.15 | - | -0.16 | -0.2 | -0.24 | -0.19 | -0.26 | -0.21 | -0.22 | -0.17 | -0.17 | -0.17 | -0.27 | -0.14 | -0.22 | -0.72 | -0.22 | - | -0.19 | -0.19 | -0.17 | - | -0.19 | -0.34 | -0.24 |
EBITDA per Share |
- | - | - | - | - | - | -0.14 | -0.16 | -0.17 | - | -0.14 | -0.14 | -0.11 | - | -0.1 | -0.11 | -0.06 | - | -0.05 | -0.06 | -0.05 | - | -0.07 | -0.1 | -0.11 | - | -0.13 | -0.13 | -0.15 | - | -0.15 | -0.19 | -0.24 | - | -0.25 | -0.2 | -0.21 | - | -0.16 | -0.15 | -0.24 | - | -0.21 | -0.16 | -0.2 | - | -0.18 | -0.17 | -0.15 | - | -0.16 | -0.26 | -0.16 |
ROE % |
72.68 | 63.05 | 98.79 | 114.69 | 154.18 | 217.93 | 104.72 | -44.22 | -155.84 | -206.48 | -232.93 | -146.17 | -118.49 | -69.48 | -75.83 | -55.73 | -35.35 | -18.59 | -71.77 | -118.60 | -185.97 | -209.66 | 622.04 | 1506.91 | 2431.68 | 2613.77 | 2569.80 | 1694.12 | 789.93 | -163.67 | -189.56 | -178.22 | -150.33 | -111.01 | -102.73 | -86.69 | -77.13 | -74.49 | -245.88 | -468.44 | -624.04 | -816.21 | -858.03 | -849.68 | -906.23 | -626.52 | -531.09 | -204.84 | 170.64 | 355.15 | 95.44 | 147.15 | 112.56 |
ROA % |
-183.87 | -149.43 | -197.42 | -198.36 | -190.11 | -114.67 | -137.07 | -111.48 | -99.64 | -75.37 | -95.45 | -93.13 | -88.49 | -52.75 | -58.49 | -44.16 | -29.69 | -16.83 | -47.39 | -72.20 | -108.65 | -120.48 | -226.41 | -301.79 | -367.49 | -332.92 | -361.58 | -284.30 | -210.90 | -106.65 | -124.34 | -117.97 | -100.61 | -75.84 | -70.72 | -60.28 | -54.26 | -53.20 | -66.75 | -87.96 | -100.16 | -112.83 | -114.83 | -109.89 | -113.97 | -76.34 | -107.01 | -109.56 | -129.03 | -114.14 | -30.67 | -47.29 | -36.18 |
ROCE % |
65.14 | 57.77 | 91.53 | 107.86 | 147.85 | 216.28 | 106.74 | -36.56 | -146.80 | -201.03 | -227.40 | -144.23 | -118.16 | -69.48 | -76.01 | -56.16 | -35.89 | -18.80 | -70.59 | -115.85 | -181.61 | -205.16 | 627.67 | 1512.29 | 2436.62 | 2617.74 | 2573.65 | 1696.74 | 791.30 | -164.03 | -196.73 | -185.35 | -157.42 | -85.34 | -101.75 | -85.45 | -75.56 | -55.18 | -294.55 | -517.51 | -673.56 | -627.95 | -876.54 | -885.76 | -942.79 | -645.24 | -549.57 | -205.31 | 164.45 | 331.15 | 95.67 | 140.75 | 94.73 |
Current Ratio |
0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.6 | 0.8 | 1.1 | 1.3 | 2.0 | 4.9 | 5.5 | 5.5 | 5.5 | 5.5 | 16.9 | 16.9 | 16.9 | 16.9 | 4.3 | 4.3 | 4.3 | 4.3 | 1.4 | 1.4 | 1.4 | 1.4 | 4.2 | 4.2 | 4.2 | 4.2 | 19.4 | 19.4 | 19.4 | 19.4 | 17.4 | 17.4 | 17.4 | 17.4 | 4.3 | 4.3 | 4.3 | 4.3 | 5.8 | 5.8 | 5.8 | 5.8 | 3.0 | 3.0 | 3.0 | 3.0 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency